UK markets closed
  • FTSE 100

    7,044.03
    -266.34 (-3.64%)
     
  • FTSE 250

    22,537.89
    -742.07 (-3.19%)
     
  • AIM

    1,181.62
    -22.34 (-1.86%)
     
  • GBP/EUR

    1.1779
    -0.0100 (-0.84%)
     
  • GBP/USD

    1.3342
    +0.0022 (+0.16%)
     
  • BTC-GBP

    40,710.55
    -243.56 (-0.59%)
     
  • CMC Crypto 200

    1,365.60
    -89.82 (-6.17%)
     
  • S&P 500

    4,594.62
    -106.84 (-2.27%)
     
  • DOW

    34,899.34
    -905.04 (-2.53%)
     
  • CRUDE OIL

    68.15
    -10.24 (-13.06%)
     
  • GOLD FUTURES

    1,788.10
    +1.20 (+0.07%)
     
  • NIKKEI 225

    28,751.62
    -747.66 (-2.53%)
     
  • HANG SENG

    24,080.52
    -659.64 (-2.67%)
     
  • DAX

    15,257.04
    -660.94 (-4.15%)
     
  • CAC 40

    6,739.73
    -336.14 (-4.75%)
     

Qiagen lifts annual forecast as COVID testing boosts third-quarter profit

  • Oops!
    Something went wrong.
    Please try again later.
·1-min read
Economy Minister Andreas Pinkwart and Health Minister Karl-Josef Laumann of the German state Northrhine Westphalia visit a testing company Qiagen, in Hilden
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

(Reuters) -Qiagen on Wednesday raised its full-year forecasts for profit and revenue, with higher demand for its non-coronavirus products as well COVID-19 tests helping the U.S.-German genetic testing specialist beat quarterly profit expectations.

The company's products include several types of ultra-rapid, portable and antigen-based coronavirus tests that have brought in millions in sales since the beginning of the pandemic.

The company said its non-COVID related products grew 17% in the third quarter, at constant exchange rates, boosted by higher demand for tuberculosis testing, which brought in $79 million.

Chief Executive Thierry Bernard said the company was on track to achieve its 2021 sales target and would cross more than $2 billion in net sales.

Qiagen said its annual revenue will grow 15% compared to the prior forecast of 12% growth. It forecast adjusted diluted earnings per share of $2.48, from prior guidance of $2.42.

Qiagen said third-quarter adjusted earnings per share rose to $0.58 on a currency-adjusted basis, beating the $0.54 expected on average by analysts.

(Reporting by Mrinalika Roy in Bengaluru; Editing by Devika Syamnath and Arun Koyyur)

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting